CRISPR Therapeutics terminates EVP R&D Tony W. Ho without cause

CRISPR Therapeutics AG

Tony W. Ho terminated as Executive Vice President, Research and Development on December 14, 2021.
Termination is without cause and not the result of any disagreement with the Company.
No replacement has been announced; Samarth Kulkarni remains CEO.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Tony W. Ho

Executive Vice President, Research and Development

CRSP · CRISPR Therapeutics AG

Effective: 2021-12-14
Filed: December 20, 2021, 6:59 PM ET

On December 14, 2021, Tony W. Ho was terminated from his position as Executive Vice President, Research and Development of CRISPR Therapeutics AG (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tony W. Ho was terminated as Executive Vice President, Research and Development at CRISPR Therapeutics AG.

Action: terminated
Role: Executive Vice President, Research and Development

Exact text from the filing

On December 14, 2021, Tony W. Ho was terminated from his position as Executive Vice President, Research and Development of CRISPR Therapeutics AG (the “Company”).

View on SEC.gov

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0001193125-21-361760

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.